文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

A cuproptosis-related lncRNA signature identified prognosis and tumour immune microenvironment in kidney renal clear cell carcinoma.

作者信息

Xin Sheng, Mao Jiaquan, Cui Kai, Li Qian, Chen Liang, Li Qinyu, Tu Bocheng, Liu Xiaming, Wang Tao, Wang Shaogang, Liu Jihong, Song Xiaodong, Song Wen

机构信息

Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China.

Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China.

出版信息

Front Mol Biosci. 2022 Sep 14;9:974722. doi: 10.3389/fmolb.2022.974722. eCollection 2022.


DOI:10.3389/fmolb.2022.974722
PMID:36188220
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9515514/
Abstract

Kidney renal clear cell carcinoma (KIRC) is a heterogeneous malignant tumor with high incidence, metastasis, and mortality. The imbalance of copper homeostasis can produce cytotoxicity and cause cell damage. At the same time, copper can also induce tumor cell death and inhibit tumor transformation. The latest research found that this copper-induced cell death is different from the known cell death pathway, so it is defined as cuproptosis. We included 539 KIRC samples and 72 normal tissues from the Cancer Genome Atlas (TCGA) in our study. After identifying long non-coding RNAs (lncRNAs) significantly associated with cuproptosis, we clustered 526 KIRC samples based on the prognostic lncRNAs and obtained two different patterns (Cuproptosis.C1 and C2). C1 indicated an obviously worse prognostic outcome and possessed a higher immune score and immune cell infiltration level. Moreover, a prognosis signature (CRGscore) was constructed to effectively and accurately evaluate the overall survival (OS) of KIRC patients. There were significant differences in tumor immune microenvironment (TIME) and tumor mutation burden (TMB) between CRGscore-defined groups. CRGscore also has the potential to predict medicine efficacy.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/db1d921d60a1/fmolb-09-974722-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/d4080930714f/fmolb-09-974722-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/ef04d2ddec26/fmolb-09-974722-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/34a094e0fbcb/fmolb-09-974722-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/5db6eb1134e6/fmolb-09-974722-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/fbfe6c1782ca/fmolb-09-974722-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/42e0f4abe19c/fmolb-09-974722-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/656929a69ec6/fmolb-09-974722-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/c8d5421224eb/fmolb-09-974722-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/2dcd4fc30079/fmolb-09-974722-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/6c9607844073/fmolb-09-974722-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/57e5b8f10351/fmolb-09-974722-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/f962516a9c87/fmolb-09-974722-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/a96ee1c9e67b/fmolb-09-974722-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/db1d921d60a1/fmolb-09-974722-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/d4080930714f/fmolb-09-974722-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/ef04d2ddec26/fmolb-09-974722-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/34a094e0fbcb/fmolb-09-974722-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/5db6eb1134e6/fmolb-09-974722-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/fbfe6c1782ca/fmolb-09-974722-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/42e0f4abe19c/fmolb-09-974722-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/656929a69ec6/fmolb-09-974722-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/c8d5421224eb/fmolb-09-974722-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/2dcd4fc30079/fmolb-09-974722-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/6c9607844073/fmolb-09-974722-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/57e5b8f10351/fmolb-09-974722-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/f962516a9c87/fmolb-09-974722-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/a96ee1c9e67b/fmolb-09-974722-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a02/9515514/db1d921d60a1/fmolb-09-974722-g014.jpg

相似文献

[1]
A cuproptosis-related lncRNA signature identified prognosis and tumour immune microenvironment in kidney renal clear cell carcinoma.

Front Mol Biosci. 2022-9-14

[2]
Clinical significance and immune landscape of cuproptosis-related lncRNAs in kidney renal clear cell carcinoma: a bioinformatical analysis.

Ann Transl Med. 2022-11

[3]
Prognostic value and immunological characteristics of a novel cuproptosis-related long noncoding RNAs risk signature in kidney renal clear cell carcinoma.

Front Genet. 2022-11-3

[4]
Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.

BMC Cancer. 2023-1-30

[5]
Identification and Validation of Cuproptosis-Related LncRNA Signatures in the Prognosis and Immunotherapy of Clear Cell Renal Cell Carcinoma Using Machine Learning.

Biomolecules. 2022-12-16

[6]
The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma.

Front Genet. 2023-1-23

[7]
Cuproptosis-related long non-coding RNAs model that effectively predicts prognosis in hepatocellular carcinoma.

World J Gastrointest Oncol. 2022-10-15

[8]
Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma.

Front Immunol. 2022

[9]
Multi-omics pan-cancer study of cuproptosis core gene and its role in kidney renal clear cell carcinoma.

Front Immunol. 2022

[10]
Molecular Subtyping Based on Cuproptosis-Related Genes and Characterization of Tumor Microenvironment Infiltration in Kidney Renal Clear Cell Carcinoma.

Front Oncol. 2022-7-6

引用本文的文献

[1]
Non-coding transcriptome profiles in clear-cell renal cell carcinoma.

Nat Rev Urol. 2025-3

[2]
Bioinformatics analysis and experimental validation of m6A and cuproptosis-related lncRNA NFE4 in clear cell renal cell carcinoma.

Discov Oncol. 2024-5-26

[3]
Identification of a lactate metabolism-related lncRNAs signature for predicting the prognosis in patients with kidney renal clear cell carcinoma.

Transl Androl Urol. 2024-4-30

[4]
Comprehensive analysis of the role of cuproptosis-related genes in the prognosis and immune infiltration of adrenocortical Carcinoma.

Heliyon. 2023-12-14

[5]
Cuproptosis-related long noncoding RNAs predicts overall survival and reveal immune microenvironment of bladder cancer.

Heliyon. 2023-11-25

[6]
A novel signature of cuproptosis-related lncRNAs predicts prognosis in glioma: Evidence from bioinformatic analysis and experiments.

Front Pharmacol. 2023-4-10

[7]
Cuproptosis: mechanisms and links with cancers.

Mol Cancer. 2023-3-7

[8]
Cuproptosis-Related MiR-21-5p/FDX1 Axis in Clear Cell Renal Cell Carcinoma and Its Potential Impact on Tumor Microenvironment.

Cells. 2022-12-31

本文引用的文献

[1]
Cuproptosis-Associated lncRNA Establishes New Prognostic Profile and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma.

Front Genet. 2022-7-15

[2]
Molecular Subtyping Based on Cuproptosis-Related Genes and Characterization of Tumor Microenvironment Infiltration in Kidney Renal Clear Cell Carcinoma.

Front Oncol. 2022-7-6

[3]
A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma.

Genes (Basel). 2022-5-10

[4]
Overexpression of FOXD2-AS1 enhances proliferation and impairs differentiation of glioma stem cells by activating the NOTCH pathway via TAF-1.

J Cell Mol Med. 2022-5

[5]
LINC01605 promotes aerobic glycolysis through lactate dehydrogenase A in triple-negative breast cancer.

Cancer Sci. 2022-8

[6]
A positive feedback loop between LINC01605 and NF-κB pathway promotes tumor growth in nasopharyngeal carcinoma.

RNA Biol. 2022

[7]
Copper induces cell death by targeting lipoylated TCA cycle proteins.

Science. 2022-3-18

[8]
Copper-induced tumor cell death mechanisms and antitumor theragnostic applications of copper complexes.

Nanomedicine (Lond). 2022-2

[9]
Landscape of Immunotherapy in Genitourinary Malignancies.

Adv Exp Med Biol. 2021

[10]
AGAP2-AS1 as a prognostic biomarker in low-risk clear cell renal cell carcinoma patients with progressing disease.

Cancer Cell Int. 2021-12-20

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索